Investors in both the adult-use / recreational cannabis space, along with the medical-hemp-CBD side of the sector are
beginning to realize one big thing, the industry as a whole has become stagnant and cash-poor, and is in desperate need of a kickstart. That’s why savvy investors are looking for companies thinking outside of the box. Or, the fruit basket, if you will.
Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF, FRA: 1OA, Forum) is a Latin American licensed producer of medicinal cannabis and cannabis-derived products, operating out of the Bogotá Savannah of central Colombia. And they are quickly gaining the attention of both public retail and private institutional investment communities in South and North America, as recently reported in a
Stockhouse Top Value Stock Editorial.
This innovative Colombian-based company has the distinction of being the first Latin American Company to have installed a machine with new stainless-steel extraction vessels that is fully compliant under European Union’s Good Manufacturing Practices (EU-GMP). They also boast
142 exclusive Colombian cannabis strains with high CBD and THC contents with all of the applicable licenses granted by the Colombian Ministries of Justice and Health.
Commencing trading on the Canadian Securities Exchange in
February 2019, the Company has made a number of strategic moves over the past 18 months to help grow its business and brand globally.
Most recently, Blueberries Medical announced a non-brokered private placement offering of $1,000,000 in financing including a strategic investment by renowned entrepreneur
Facundo Garreton – a successful international businessman and Yale University World Greenberg World Fellow. Mr. Garreton has built and developed many businesses in Latin America and globally, including the founding of InvertirOnline.com – one of Latin America’s largest online brokerage firms.
Mr. Garreton commented:
“I am very happy to join the Blueberries team. I consider it to be one of the cannabis companies with the greatest potential in Latin America, not only for its productive operations in Colombia, but also for the excellent team and unique extraction capabilities, which complement other initiatives in which I am involved. I am increasingly committed to this exciting cannabis industry, in a world where more and more people are suffering from various medical conditions and scientific research suggests that cannabis has significant therapeutic potential to improve their quality of life. We will work with Blueberries on various initiatives, including research and the cannabis production value chain to help many people with ailments and with alternative solutions based on the cannabis plant.”
Camilo Villalba, CEO of Blueberries, added:
“We are excited to announce the strategic investment from Mr. Garreton. This investment from a successful entrepreneur with deep industry knowledge and relationships in Latin America is highly strategic and will provide significant value to Blueberries as we enter this exciting phase of our business development.”
The Company says it intends to use the proceeds from the offering mainly for “inventory production, product launch, commercialization and additional capital investments at its GMP-compliant extraction and processing facility.”
On
June 8, 2020, BBM announced a partnership with Medicamentos de Cannabis SAS (Medcann) to develop, and produce THC cannabis extracts for the international market. Both companies will work together in the manufacturing and commercialization, taking advantage of market dynamics and the commercial THC quotas to be assigned to Blueberries.
BBM’s Operational Efficiencies:
- Strategic extraction and processing model
- Industry leading operational costs thanks to ideal climate and efficient labor force
- Scalable growing capacity through contract growers
- 142 exclusive Colombian cannabis strains with high CBD and THC contents
- Strong global partnerships for product development and distribution
The Final Word
Blueberries Medical is a fully licensed producer (LP) of medical cannabis flower and oil products in Colombia from its state-of-the-art facilities that are now EU GMP-compliant. This designation is a must when it comes to exporting medical cannabis to international markets.
At present, the 30,000 square foot indoor facility has an extraction capacity of 70,000 kilograms a year of dried flower with the ability to accommodate significant future expansion with additional extraction lines. But this is just the start of something even bigger as Blueberries Medical plans to further expand its indoor-outdoor cultivation footprint to
5.2 million square feet by 2022.
For investors looking for something fresh in the growing international cannabis marketplace, these ‘Blueberries’ look like a very sweet deal.
https://www.blueberriesmed.com/en/about-us
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.